225 related articles for article (PubMed ID: 33890484)
1. ARID1 proteins: from transcriptional and post-translational regulation to carcinogenesis and potential therapeutics.
Odnokoz O; Wavelet-Vermuse C; Hophan SL; Bulun S; Wan Y
Epigenomics; 2021 May; 13(10):809-823. PubMed ID: 33890484
[TBL] [Abstract][Full Text] [Related]
2. Dynamics of expression of ARID1A and ARID1B subunits in mouse embryos and in cells during the cell cycle.
Flores-Alcantar A; Gonzalez-Sandoval A; Escalante-Alcalde D; Lomelí H
Cell Tissue Res; 2011 Jul; 345(1):137-48. PubMed ID: 21647563
[TBL] [Abstract][Full Text] [Related]
3. Dual ARID1A/ARID1B loss leads to rapid carcinogenesis and disruptive redistribution of BAF complexes.
Wang Z; Chen K; Jia Y; Chuang JC; Sun X; Lin YH; Celen C; Li L; Huang F; Liu X; Castrillon DH; Wang T; Zhu H
Nat Cancer; 2020 Sep; 1(9):909-922. PubMed ID: 34386776
[TBL] [Abstract][Full Text] [Related]
4. SWI/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability.
Watanabe R; Ui A; Kanno S; Ogiwara H; Nagase T; Kohno T; Yasui A
Cancer Res; 2014 May; 74(9):2465-75. PubMed ID: 24788099
[TBL] [Abstract][Full Text] [Related]
5. Co-regulation of transcription by BRG1 and BRM, two mutually exclusive SWI/SNF ATPase subunits.
Raab JR; Runge JS; Spear CC; Magnuson T
Epigenetics Chromatin; 2017 Dec; 10(1):62. PubMed ID: 29273066
[TBL] [Abstract][Full Text] [Related]
6. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers.
Kelso TWR; Porter DK; Amaral ML; Shokhirev MN; Benner C; Hargreaves DC
Elife; 2017 Oct; 6():. PubMed ID: 28967863
[TBL] [Abstract][Full Text] [Related]
7. Genome-Wide Transcriptional Regulation Mediated by Biochemically Distinct SWI/SNF Complexes.
Raab JR; Resnick S; Magnuson T
PLoS Genet; 2015 Dec; 11(12):e1005748. PubMed ID: 26716708
[TBL] [Abstract][Full Text] [Related]
8. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
[TBL] [Abstract][Full Text] [Related]
9. HIC1 interacts with a specific subunit of SWI/SNF complexes, ARID1A/BAF250A.
Van Rechem C; Boulay G; Leprince D
Biochem Biophys Res Commun; 2009 Aug; 385(4):586-90. PubMed ID: 19486893
[TBL] [Abstract][Full Text] [Related]
10. mRNA Display Identifies Potent, Paralog-Selective Peptidic Ligands for ARID1B.
Cremosnik GS; Mesrouze Y; Zueger P; Furkert D; Grandjean F; Argoti D; Mermet-Meillon F; Bauer MR; Brittain S; Rogemoser P; Yang W; Giovannoni J; McGregor L; Tang J; Knapp M; Holzinger S; Buhr S; Muller L; Leder L; Xie L; Fernandez C; Nieto-Oberhuber C; Chène P; Galli GG; Sesterhenn F
ACS Chem Biol; 2024 May; 19(5):1142-1150. PubMed ID: 38655884
[TBL] [Abstract][Full Text] [Related]
11. The BRG1 ATPase of human SWI/SNF chromatin remodeling enzymes as a driver of cancer.
Wu Q; Lian JB; Stein JL; Stein GS; Nickerson JA; Imbalzano AN
Epigenomics; 2017 Jun; 9(6):919-931. PubMed ID: 28521512
[TBL] [Abstract][Full Text] [Related]
12. Glioma tumor suppressor candidate region gene 1 (GLTSCR1) and its paralog GLTSCR1-like form SWI/SNF chromatin remodeling subcomplexes.
Alpsoy A; Dykhuizen EC
J Biol Chem; 2018 Mar; 293(11):3892-3903. PubMed ID: 29374058
[TBL] [Abstract][Full Text] [Related]
13. Dissecting the role of SWI/SNF component ARID1B in steady-state hematopoiesis.
Madan V; Shyamsunder P; Dakle P; Woon TW; Han L; Cao Z; Nordin HBM; Jizhong S; Shuizhou Y; Hossain MZ; Koeffler HP
Blood Adv; 2023 Nov; 7(21):6553-6566. PubMed ID: 37611161
[TBL] [Abstract][Full Text] [Related]
14. The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer.
Hodges C; Kirkland JG; Crabtree GR
Cold Spring Harb Perspect Med; 2016 Aug; 6(8):. PubMed ID: 27413115
[TBL] [Abstract][Full Text] [Related]
15. BAFfling pathologies: Alterations of BAF complexes in cancer.
Arnaud O; Le Loarer F; Tirode F
Cancer Lett; 2018 Apr; 419():266-279. PubMed ID: 29374542
[TBL] [Abstract][Full Text] [Related]
16. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers.
Hoffman GR; Rahal R; Buxton F; Xiang K; McAllister G; Frias E; Bagdasarian L; Huber J; Lindeman A; Chen D; Romero R; Ramadan N; Phadke T; Haas K; Jaskelioff M; Wilson BG; Meyer MJ; Saenz-Vash V; Zhai H; Myer VE; Porter JA; Keen N; McLaughlin ME; Mickanin C; Roberts CW; Stegmeier F; Jagani Z
Proc Natl Acad Sci U S A; 2014 Feb; 111(8):3128-33. PubMed ID: 24520176
[TBL] [Abstract][Full Text] [Related]
17. ARID1A-mutated ovarian cancers depend on HDAC6 activity.
Bitler BG; Wu S; Park PH; Hai Y; Aird KM; Wang Y; Zhai Y; Kossenkov AV; Vara-Ailor A; Rauscher FJ; Zou W; Speicher DW; Huntsman DG; Conejo-Garcia JR; Cho KR; Christianson DW; Zhang R
Nat Cell Biol; 2017 Aug; 19(8):962-973. PubMed ID: 28737768
[TBL] [Abstract][Full Text] [Related]
18. ARID1A-dependent maintenance of H3.3 is required for repressive CHD4-ZMYND8 chromatin interactions at super-enhancers.
Reske JJ; Wilson MR; Armistead B; Harkins S; Perez C; Hrit J; Adams M; Rothbart SB; Missmer SA; Fazleabas AT; Chandler RL
BMC Biol; 2022 Sep; 20(1):209. PubMed ID: 36153585
[TBL] [Abstract][Full Text] [Related]
19. ARID1B is a specific vulnerability in ARID1A-mutant cancers.
Helming KC; Wang X; Wilson BG; Vazquez F; Haswell JR; Manchester HE; Kim Y; Kryukov GV; Ghandi M; Aguirre AJ; Jagani Z; Wang Z; Garraway LA; Hahn WC; Roberts CW
Nat Med; 2014 Mar; 20(3):251-4. PubMed ID: 24562383
[TBL] [Abstract][Full Text] [Related]
20. The Tumor Suppressor ARID1A Controls Global Transcription via Pausing of RNA Polymerase II.
Trizzino M; Barbieri E; Petracovici A; Wu S; Welsh SA; Owens TA; Licciulli S; Zhang R; Gardini A
Cell Rep; 2018 Jun; 23(13):3933-3945. PubMed ID: 29949775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
